|
CA3113345A1
|
|
Drug delivery devices and systems for local drug delivery to the upper urinary tract
|
|
AU2019315957A1
|
|
Methods of treating overactive bladder using trospium
|
|
CA3080401A1
|
|
Drug delivery devices and methods for use with a urinary catheter
|
|
CA3081839A1
|
|
Methods of treatment and maintenance therapy for bladder cancer using gemcitabine
|
|
CN110944645A
|
|
Method for treating tumor metastasis
|
|
MX2019009080A
|
|
In vivo drug delivery devices and methods for drug delivery.
|
|
MX2018013432A
|
|
Method of treating lower tract urothelial cancer.
|
|
WO2017151983A1
|
|
Osmotic drug delivery devices and methods of making osmotic drug delivery devices
|
|
US2019083767A1
|
|
Multi-lumen drug delivery devices
|
|
US2018199816A1
|
|
Urodynamic assessment sysrems and methods
|
|
EP3285850A1
|
|
Drug delivery devices with drug-permeable component and methods
|
|
KR20170132189A
|
|
Apparatus and method for local delivery of drug to upper urinary tract
|
|
WO2016044624A1
|
|
Methods and systems for diagnostic mapping of bladder
|
|
US2017246437A1
|
|
pH-MODULATING DRUG DELIVERY DEVICES AND METHODS
|
|
EP3160442A1
|
|
Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems
|
|
KR20170016853A
|
|
Drug delivery devices and methods
|
|
AU2015226901A1
|
|
Drug delivery systems and methods for treatment of bladder cancer with gemcitabine
|
|
AU2015201123A1
|
|
Implantable device with intravesical tolerability and methods of treatment
|
|
CA2929554A1
|
|
Osmotic drug delivery devices, kits, and methods
|
|
HUE051336T2
|
|
Multi-unit drug delivery devices
|
